RZLT ▼ -3.0% - Rezolute, Inc. $RZLT - Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism Rezolute shares fell 3.0% following the company's update on FDA review of Phase 3 sunRIZE study results for its congenital hyperinsulinism treatment. The headline does not specify whether the FDA feedback was positive or negative, though regulatory milestones—particularly those involving ongoing review processes—can trigger modest sell-offs if investors interpret the timing or framing as indicating delays or conditional approval pathways. 09-SEP-2026 07:01 AM ET